Check this out!! If this doesn't get you fired up I don't know what will. This is exactly how MYGN grew. We are on the verge of major growth and revenue.
Scientific validation and clinical utility studies
− Further scientific validation results/publications expected by end Q1 FY16
− Evidence from clinical utility studies will secure wider payer coverage, increase current reimbursement levels and speed product uptake – first of three trials to begin Q2 FY16, completion expected end FY16
-Negotiations to contract with Insurers directly, will commence once supporting clinical utility studies published – mid to end calendar 2015
-Recoverability at 65% - with average revenue per test recovered, approximately USD470 (AUD645 @73 cents)
- Gross Margin is 95% on list price; and 75% on average payment received
- Total number of women in target age range for BREVAGenplus: 54.3 million